Bausch Health, recognized previously as Valeant Pharmaceuticals, is carving out a distinct identity in the competitive landscape of the pharmaceutical industry. With its global headquarters situated in Canada, the company focuses on various therapeutic areas, including dermatology, gastroenterology, neurology, and ophthalmology. Its operations are segmented into five main divisions: Bausch + Lomb, Salix Pharmaceuticals, International Rx, Solta Medical, and Diversified Products. The prominence of Bausch Health in the healthcare sector is largely attributed to the robust performance of its Bausch + Lomb division, which specializes in eye care.
In early 2021, Bausch Health found itself in the crosshairs of scrutiny from activist investor Carl Icahn, who filed a 13D with the U.S. Securities and Exchange Commission. Icahn’s entry into the company’s fold represented a significant turning point, as he expressed intentions to engage with the management and board in discussions aimed at enhancing shareholder value. This included a meticulous strategic review process that was already underway, facilitating a pivotal partnership that led to an agreement to increase board size and involve Icahn’s associates in its direction.
By May 2022, a notable restructuring occurred when Bausch + Lomb was spun off as an independent publicly traded entity. Despite this separation, Bausch Health retains an 88% ownership stake, positioning itself uniquely in the market with an eye on strategic oversight. Following this transition, Richard Mulligan, a former Icahn portfolio manager, joined the board, bringing with him insights that potentially align stakeholder interests with operational strategies.
Recent reports have portrayed Bausch + Lomb (BLCO) as a viable candidate for acquisition, with Goldman Sachs engaged to explore potential sale avenues. BLCO’s current enterprise value is approximately $10 billion, influenced significantly by Bausch Health’s overarching debt of $20.4 billion, of which BLCO accounts for $4.6 billion. The interplay between ownership structure and market valuation has left BLCO’s stocks trading at depressed levels compared to estimated earnings figures, particularly when examining the potential earnings before interest, taxes, depreciation, and amortization (EBITDA) projected to be around $966 million by 2025.
When compared to industry peers such as The Cooper Companies and Alcon, which trade at enterprise value/EBITDA multiples of 19.5 and 18.5, respectively, there is a strong argument for BLCO’s undervaluation. If BLCO were to be valued at a more representative average multiple of 19, it could command an enterprise value closer to $18.35 billion, hinting at an echelon where shareholders could see substantial returns if acquisition talks materialize.
Salix Pharmaceuticals, a vital segment within Bausch Health, has been primarily reliant on the Xifaxan drug, which is poised to lose patent protection in January 2028. Its overwhelming contribution—87% of the Salix division’s income—adds a layer of fragility that warrants closer analysis. Despite the current robust revenue stream, the impending patent loss has prompted a reassessment of the division’s long-term viability and potential value.
Should Xifaxan’s revenue continue a conservative projected growth rate, its present value up to the expiration could still amount to $4.25 billion. This suggests that the forthcoming years will be critical for Salix, as management will need to explore avenues for diversification and innovation to sustain revenue streams.
With the sale of BLCO and the projected earnings from Salix, it becomes important to appraise the remaining divisions under Bausch Health’s umbrella. The International Rx segment and Diversified Products division possess potential that can contribute significantly to the overall value of the company. With a myriad of peers trading on various multiples, a cautious estimate using an 8-times multiple for the collective operating income of the remaining segments suggests an approximate value of $9.36 billion.
After factoring sales from BLCO and the capital generated from the Xifaxan portfolio, the total valuation for Bausch Health could ascend to $25.93 billion. When mapped against the debts outlined, the company may emerge with an equity value poised at $10.49 billion, translating into a per-share value dramatically higher than the current trading price, underscoring the latent potential yet to be realized.
In a corporate landscape characterized by volatility and unfounded speculation, the path for Bausch Health appears riddled with hurdles. The complexities surrounding ownership structuring, executive acumen among board members, and the precise timing for an eventual sale will be paramount. Historically, M&A processes elicit skepticism regarding their fruition, and this environment is no different. However, with a board comprising hedge fund managers, there may exist a strategic mindset geared towards unlocking value, fostering optimism for shareholders looking for a rebound in equity performance.
Bausch Health’s evolution from Valeant Pharmaceuticals encapsulates a narrative of adaptation and anticipation. As they navigate through strategic engagement and potential divestitures, the focus must remain steadfast on enhancing shareholder value while adeptly managing inheritances from its past, allowing the company to thrive in an otherwise challenging healthcare landscape.
Leave a Reply